Date 30/06/2008 |
SUSPENSION OF SHARES FOR TRADING ON THE OFFICIAL LIST, ENTRY INTO VOLUNTARY ADMINISTRATION |
Edinburgh, 30 June 2008: Ardana PLC announces that, at its own request, trading in the Company's ordinary shares was suspended with effect from 16.25 on Friday 27 June 2008, following which the Board has agreed to appoint Mr David Duggins and Mr Tom Burton of Ernst & Young LLP to act as Administrators of the Company from today. |
| |
Date 13/05/2008 |
ARDANA ANNOUNCES A PRELIMINARY EVALUATION OF ITS TESTOSTERONE CREAM PIVOTAL STUDY AND PROVIDES AN UPDATE ON VARIOUS STRATEGIC OPTIONS |
Edinburgh, UK: 13 May 2008: Ardana plc (“the Company”) (LSE:ARA) the pharmaceutical company specialising in improving human reproductive health, today announces a preliminary evaluation of its Testosterone Cream in a Phase III study in hypogonadal men and provides an update on the progress of the various strategic options currently being pursued by the Company. |
| |
Date 02/05/2008 |
RNS Block Listing |
|
| |
Date 09/04/2008 |
ARDANA ANNOUNCES PRELIMINARY PHASE II REPEAT DOSE RESULTS FOR TEVERELIX LA IN PROSTATE CANCER
|
Edinburgh, UK: 9 April 2008 : Ardana plc (LSE:ARA) today announces preliminary results from a Phase II repeat dose study of its lead development compound, the GnRH antagonist Teverelix LA (Long-Acting), in patients with prostate cancer demonstrating testosterone suppression for 28 weeks using an alternative formulation for the first time.
|
| |
Date 27/03/2008 |
UPDATE ON THE PROPOSED SALE OR MERGER OF THE COMPANY |
Edinburgh, UK, 27 March 2008 - Ardana plc (“Ardana” or the “Company”) (LSE:ARA) the pharmaceutical company specialising in improving human reproductive health, today provides an update to shareholders on developments in relation to the proposed sale or merger of the Company (the “Process”), as announced on 19 February 2008 |
| |
Date 18/03/2008 |
| ARDANA ANNOUNCES POSITIVE RESULTS FROM A PHASE I STUDY OF TESTOSTERONE CREAM IN FEMALE SUBJECTS |
Edinburgh, UK, 18 March 2008 - Ardana plc (LSE:ARA) the pharmaceutical company specialising in improving human reproductive health, today announces positive results of its Testosterone Cream in a Phase I study to evaluate the absorption of testosterone in women from their unique cream formulation . This Phase I dose-finding study provided clear evidence of the effectiveness of Ardana’s cream in the transdermal delivery of testosterone in females. |
| |
Date 28/02/2008 |
| VOTING RIGHTS AND CAPITAL |
Edinburgh, UK, February 28, 2008: Ardana plc (LSE:ARA), in conformity with the Transparency Directive’s transitional provision 6, today notifies the market of the following:
|
| |
Date 19/02/2008 |
|
INTERIM MANAGEMENT STATEMENT - THREE MONTHS ENDED 31 DECEMBER 2007
|
Edinburgh, UK, February 19, 2008: Ardana plc (LSE:ARA), the emerging pharmaceutical company focused on the discovery, development and marketing of innovative products to improve human reproductive health, is today issuing its third quarter Interim Management Statement (“IMS”) and provides an update on the business. This IMS has been produced solely to provide additional information to shareholders as a body to meet the relevant requirements of the UK Listing Authority’s Disclosure and Transparency Rules. It should not be relied upon by any other party or for any other purpose.
This IMS relates to the three month period from 1 October 2007 to 31 December 2007 and contains information that covers this period and the period from 1 January 2008 up to the publication of this IMS (“the period”), unless otherwise specified.
|
| |
Date 19/02/2008 |
|
PROPOSED SALE OR MERGER OF THE COMPANY |
Edinburgh, UK, February 19, 2008: Ardana plc (LSE:ARA), the emerging pharmaceutical company focused on the discovery, development and marketing of innovative products to improve human reproductive health, today announces that it is seeking to sell or merge the Company in order that the value of its pipeline can be maximised. Piper Jaffray Ltd. has been appointed to advise the Company in connection with this process.
|
| |
Date 09/01/2008 |
|
ARDANA ANNOUNCES OUTCOME OF PRE-IND MEETING WITH FDA ON TEVERELIX LA FOR THE TREATMENT OF ENDOMETRIOSIS |
Edinburgh, UK, January 9, 2008: Ardana Plc (LSE:ARA), the emerging pharmaceutical company specialising in improving human reproductive health, today announces the positive outcome of a pre-Investigational New Drug (IND) meeting with the United States Food and Drug Administration (FDA) for the development of its lead compound Teverelix LA (long-acting) for the treatment of endometriosis |
| |
